Abstract
Scedosporium apiospermum and prolificans are ubiquitous filamentous fungal organisms histologically indistinguishable from Aspergillus, that display intrinsic resistance to many anti-fungal agents, including amphotericin B. In immunocompromised hosts, they may cause severe pulmonary and disseminated infection or asymptomatic colonization. Voriconazole is a promising triazole agent for Scedosporium species (SS), with low minimal inhibitory concentration and high oral bioavailability. However, there are few data correlating this in-vitro susceptibility with clinical response. Aim: To describe the epidemiology of Scedosporium infection in our lung transplant (LTx) population and the therapeutic response to voriconazole.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
